Together, these data genetically validate the potential importance of targeting ERO1A for the treatment of EGFRMUT-NSCLC and provide rationale to further understand the mechanism underpinning the role of ERO1A in meditating the progression of EGFRMUT-NSCLC. Here, ERO1A is linked to non-small cell lung carcinoma.